Clinical Trial Update: Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, reactogenicity and immunogenicity of GlaxoSmithKline's non-typeable Haemophilus influenzae vaccine; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Diseases

Drugs mentioned

• NTHi vaccine (Non-typeable Haemophilus influenzae vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Disorders | Phase 1 | Status: COMPLETED